Drug intelligence / Profile preview

SIRA-68

Development stage: Discontinued
Lead developer: Siragen
Modality: Small Molecules

Overview

SIRA-68 is a small molecule drug candidate developed by Siragen Pharmaceuticals, Inc. It functions as a phosphotransferases inhibitor, targeting a class of enzymes crucial for cellular signaling, metabolism, and regulation. The drug was being developed for therapeutic applications in Nervous System Diseases, including age-related neurodegenerative disorders such as Alzheimer's disease. Siragen Pharmaceuticals designed its small molecule candidates using a structure-guided approach to achieve intrasteric regulation as their mode of action, aiming for target specificity.

Beyond the preview

Go deeper on SIRA-68.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIRA-68.

Explore the full profile